Why a onetime biotech IPO hopeful shifted to a 'blank check' deal
November 08, 2021 at 18:02 PM EST
The company's lead drug targets a deadly lung-scarring disease and could start a mid-stage clinical trial in the first half of next year.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|